Pipeline 

VitroScan participates in multiple research collaborations and grant consortia. A clinical trial program is initiated in collaboration with (academic) medical centers for selected solid cancers, including ovarian cancer, bladder cancer, pancreatic cancer, and mesothelioma. 

Drug developers

We offer in-depth drug sensitivity evaluation for patient selection in the context of clinical trials:

• Early characterization of responsive subgroup
• Identification of predictive biomarkers
• Correlation with genetic markers
• Benchmark against standard of care drugs
• Refine Market Access proposition

Research institutes

VitroScan performs advanced functional testing using tumor samples to evaluate the sensitivity of registered and novel drug therapies including chemotherapy, small molecules, antibodies, ADC’s, immuno-oncology.